Axsome Therapeutics, Inc. annual earnings per share (EPS) for fiscal 2025 was $-3.68, an increase of 38.6% from $-5.99 in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Diluted EPS | ($4M) | ($6M) | ($5M) | ($5M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Diluted EPS | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More AXSM metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow
All AXSM financial statements → Interactive AXSM charts →
About TickerBase · Data methodology & sources